MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

Compugen Ltd

Cerrado

1.43 -2.05

Resumen

Variación precio

24h

Actual

Mínimo

1.41

Máximo

1.47

Métricas clave

By Trading Economics

Ingresos

-7.4M

-6.1M

Ventas

-16M

1.5M

P/B

Media del Sector

60.333

57.333

BPA

-0.07

Margen de beneficio

-415.84

Empleados

74

EBITDA

-12M

-7.5M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+170.27% upside

Dividendos

By Dow Jones

Próximas Ganancias

19 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-624M

136M

Apertura anterior

3.48

Cierre anterior

1.43

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Compugen Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2025, 23:27 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 abr 2025, 23:07 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 abr 2025, 23:03 UTC

Ganancias

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 abr 2025, 23:47 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 abr 2025, 22:57 UTC

Principales Noticias

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 abr 2025, 22:46 UTC

Ganancias

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Comparación entre iguales

Cambio de precio

Compugen Ltd Esperado

Precio Objetivo

By TipRanks

170.27% repunte

Estimación a 12 meses

Media 4 USD  170.27%

Máximo 4 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.38 / 1.48Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.